Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial

Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial

Introduction A December 2019 WHO rapid communication recommended the use of 9-month all-oral regimens for treating multidrug-resistant tuberculosis (MDR-TB). Besides the clinical benefits, they are thought to be less costly than the injectable-containing regimens, for both the patient and the health...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bruce Kirenga, Andrew Nunn, Ewan Tomeny, Jason Madan, Bertel Squire, Laura Rosu, Eve Worrall, Mamo Girma, Vanita Patel, Makwana Mukesh, Malaisamy Muniyandi, Shravan Kumar, Sangeetha Subramani, Saleem Ahmad, Jasper Nidoi, Irina Pirlog, Mariana Macarie, ID Rusen, Gay Bronson, Meera Gurumurthy, Karen Sanders, Sarah Meredith, Wendy Dodds Ben Spittle, Robyn Henry-Cockles, Rachel Bennett, Elisa Giallongo, Danni Maas, Ruth Goodall, Saiam Ahmed, Claire Cook, Katharine Bellenger, Gopalan Narendran, Elena Tudor, Rajesh Solanki, Daniel Meressa, Adamu Bayissa, Anuj Bhatnagar
Formato: article
Lenguaje:EN
Publicado: BMJ Publishing Group 2020
Materias:
Medicine
R
Acceso en línea:https://doaj.org/article/a9fcc9bd4f9a4b70a682711333f0f708
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/a9fcc9bd4f9a4b70a682711333f0f708

Ejemplares similares